Nuvectis Pharma, Inc. (NASDAQ:NVCT)
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$27.8M
- Net margin
- —
Little or no net debt.
- Total debt
- $0
- Cash
- $22.2M
- Debt / equity
- 0.00
Comfortably covers what is due within a year.
- Current assets
- $22.4M
- Current liabilities
- $13.3M
- Current ratio
- 1.68
Consumes cash and must keep raising it.
- Operating cash flow
- -$19.5M
- Free cash flow
- -$19.5M
Some dilution over the past year.
- Shares outstanding
- 23.5M
- Share growth (1y)
- 9.9%
- Cash runway
- 14 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NVCT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 2.51 M | 2.15 M | 2.53 M | 2.02 M | 2.98 M | 1.89 M |
| R&D Expense | 4.68 M | 4.11 M | 5.09 M | 5.77 M | 3.61 M | 3.68 M |
| Operating Expenses | 7.20 M | 6.26 M | 7.62 M | 7.79 M | 6.59 M | 5.57 M |
| Operating Income | -7.20 M | -6.26 M | -7.62 M | -7.79 M | -6.59 M | -5.57 M |
| Pretax Income | -7.02 M | -6.05 M | -7.31 M | -7.46 M | -6.33 M | -5.33 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -7.02 M | -6.05 M | -7.31 M | -7.46 M | -6.33 M | -5.33 M |
| EPS (Basic) | -0.30 | -0.26 | -0.31 | -0.44 | -0.30 | -0.27 |
| EPS (Diluted) | -0.30 | -0.26 | -0.31 | -0.44 | -0.30 | -0.27 |
| Shares Outstanding | 23.48 M | 23.41 M | 21.81 M | 22.72 M | 21.37 M | 19.94 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.